Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

Summary Background Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepa...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Alimentary pharmacology & therapeutics Ročník 49; číslo 10; s. 1323 - 1333
Hlavní autoři:	Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Wiley Subscription Services, Inc 01.05.2019 John Wiley and Sons Inc
Témata:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Apoptosis Austria Carcinoma, Hepatocellular - drug therapy Cell death Diarrhea Disease control Female Germany Hepatitis Hepatocellular carcinoma Humans Immunotherapy Liver cancer Liver Neoplasms - drug therapy Male Middle Aged Monoclonal antibodies Nivolumab - therapeutic use Original Pembrolizumab Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma Proteins Pruritus Retrospective Studies Safety Targeted cancer therapy Austria Germany
ISSN:	0269-2813, 1365-2036, 1365-2036
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!